Bristol Taking A Cautious Approach To Triple Immuno-Oncology Combos
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is starting to explore triple immuno-oncology combinations, Head of Oncology-Global Clinical Research Jean Viallet said, but IO development is mainly focused on expanding the firm's existing double combination, Opdivo and Yervoy, to earlier treatment and new tumors.